Clinical trial
Liposomal Bupivacaine/Bupivacaine A Single-Dose Bilateral Rectus Sheath Blocks Versus Ropivacaine in Bilateral Rectus Sheath Blocks And Catheters With Intermittent Hourly Boluses.
NCT05972018 is registered in ClinicalTrials.gov with Hartford Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Liposomal Bupivacaine/Bupivacaine A Single-Dose Bilateral Rectus Sheath Blocks Versus Ropivacaine in Bilateral Rectus Sheath Blocks And Catheters With Intermittent Hourly Boluses.
- Lead sponsor
- Hartford Hospital
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- October 18, 2023
- Completion date
- December 30, 2026
- Enrollment
- 14 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
abdominal aortic occlusion, aortic aneurysm, abdominal, aortic diseases, aortoiliac occlusive disease